Efficacy and Pharmacokinetics of Meropenem in Severe Septic Patients

• Status: Completed
• Trial end date: 2019-12-14
• Target enrollment: 0
• Participant gender: All

Summary

The experimental and control group were used different administration of Meropenem through monitoring the Meropenem plasma concentration and clinical data

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
• Treatments: Meropenem

Criteria

Inclusion Criteria:

1. Inpatients, whose informed consent has been obtained;

2. Clinical diagnosis of Sepsis

Exclusion Criteria:

1. Pregnancy or lactation;

2. Treated with other carbapenems;

3. Cannot be evaluated for efficacy and safety result from lack of clinical and laboratory parameter for Infection assessment;

4. Allergy to meropenem or other β-lactams, or the history of allergy;

5. Resistant to meropenem according to the antimicrobial susceptibility test;

6. Epilepsy or history of epilepsy;

7. History of seizures;

8. Combined medicine with sodium valproate;

9. Combined medicine with anti-MRSA, anti-fungal drugs;

10. with severe liver or renal dysfunction;

11. Terminal cancer;

12. Septic shock;

13. APACH II ≥20;

14. Inappropriate to participate in the trial evaluated by investigator.